[go: up one dir, main page]

ES2185708T3 - Inhibicion de la biosintesis de leucotrienos con derivados de urea. - Google Patents

Inhibicion de la biosintesis de leucotrienos con derivados de urea.

Info

Publication number
ES2185708T3
ES2185708T3 ES95926593T ES95926593T ES2185708T3 ES 2185708 T3 ES2185708 T3 ES 2185708T3 ES 95926593 T ES95926593 T ES 95926593T ES 95926593 T ES95926593 T ES 95926593T ES 2185708 T3 ES2185708 T3 ES 2185708T3
Authority
ES
Spain
Prior art keywords
biosynthesis
leucotriens
urea
inhibition
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95926593T
Other languages
English (en)
Inventor
Stephen L Crooks
Bryon A Merrill
Paul D Wightman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Co
Original Assignee
Minnesota Mining and Manufacturing Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/455,643 external-priority patent/US5612377A/en
Application filed by Minnesota Mining and Manufacturing Co filed Critical Minnesota Mining and Manufacturing Co
Application granted granted Critical
Publication of ES2185708T3 publication Critical patent/ES2185708T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

METODO PARA INHIBIR LA BIOSINTESIS DE LEUCOTRIENO, QUE SUPONE LA ADMINISTRACION DE UN COMPUESTO DE LA FORMULA (I) DONDE M, R, R`, R``, Y N SON COMO SE DEFINEN AQUI. TAMBIEN, COMPOSICION FARMACEUTICA QUE IMPLICA DICHO COMPUESTO Y EL USO DE ESTOS COMPUESTOS EN LA FABRICACION DE UNA COMPOSICION FARMACEUTICA PARA INHIBIR LA BIOSINTESIS DE LEUCOTRIENO.
ES95926593T 1994-08-04 1995-07-14 Inhibicion de la biosintesis de leucotrienos con derivados de urea. Expired - Lifetime ES2185708T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28601794A 1994-08-04 1994-08-04
US08/455,643 US5612377A (en) 1994-08-04 1995-05-31 Method of inhibiting leukotriene biosynthesis

Publications (1)

Publication Number Publication Date
ES2185708T3 true ES2185708T3 (es) 2003-05-01

Family

ID=26963530

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95926593T Expired - Lifetime ES2185708T3 (es) 1994-08-04 1995-07-14 Inhibicion de la biosintesis de leucotrienos con derivados de urea.

Country Status (19)

Country Link
EP (1) EP0777471B1 (es)
JP (1) JPH10503771A (es)
AT (1) ATE228359T1 (es)
AU (1) AU685980B2 (es)
BR (1) BR9508521A (es)
CA (1) CA2196701A1 (es)
CZ (1) CZ287034B6 (es)
DE (1) DE69528984T2 (es)
DK (1) DK0777471T3 (es)
ES (1) ES2185708T3 (es)
FI (1) FI970452A0 (es)
HU (1) HUT76830A (es)
IL (1) IL114646A (es)
NO (1) NO315786B1 (es)
NZ (1) NZ290236A (es)
PL (1) PL180668B1 (es)
PT (1) PT777471E (es)
SK (1) SK282777B6 (es)
WO (1) WO1996003983A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
FR2880022B1 (fr) * 2004-12-24 2007-08-24 Mayoly Spindler Soc Par Action Nouveaux derives de la n-hydroxy-n'-phenyluree et de la n-hydroxy-n'-phenylthiouree et leur utilisation comme inhibiteurs de la synthese de la melanine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066658A (en) * 1988-11-10 1991-11-19 Ortho Pharmaceutical Corporation Substituted hydroxyureas
WO1990008545A1 (en) * 1989-02-01 1990-08-09 Abbott Laboratories Lipoxygenase inhibiting compounds
JP2528741B2 (ja) * 1991-01-09 1996-08-28 ファイザー製薬株式会社 オキサゾ―ル、チアゾ―ルおよびイミダゾ―ル化合物

Also Published As

Publication number Publication date
CZ287034B6 (en) 2000-08-16
FI970452A7 (fi) 1997-02-03
PL180668B1 (pl) 2001-03-30
NO970477L (no) 1997-03-14
EP0777471B1 (en) 2002-11-27
NZ290236A (en) 1998-12-23
CA2196701A1 (en) 1996-02-15
DE69528984D1 (de) 2003-01-09
FI970452L (fi) 1997-02-03
BR9508521A (pt) 1997-10-28
NO970477D0 (no) 1997-02-03
PL318539A1 (en) 1997-06-23
FI970452A0 (fi) 1997-02-03
AU3091795A (en) 1996-03-04
IL114646A (en) 2000-02-29
SK11097A3 (en) 1997-09-10
CZ31297A3 (en) 1997-09-17
ATE228359T1 (de) 2002-12-15
PT777471E (pt) 2003-04-30
JPH10503771A (ja) 1998-04-07
WO1996003983A1 (en) 1996-02-15
DE69528984T2 (de) 2003-09-04
IL114646A0 (en) 1995-11-27
NO315786B1 (no) 2003-10-27
EP0777471A1 (en) 1997-06-11
DK0777471T3 (da) 2003-03-17
MX9700860A (es) 1997-10-31
AU685980B2 (en) 1998-01-29
HUT76830A (en) 1997-11-28
SK282777B6 (sk) 2002-12-03

Similar Documents

Publication Publication Date Title
MX9308199A (es) Inhibidores de enzima.
ES2128552T3 (es) Combinacion de un inhibidor de la biosintesis del colesterol y un inhibidor de la absorcion del colesterol beta-lactama.
ES2122076T3 (es) Derivados de nor-acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos.
ES2185155T3 (es) Agentes conservantes de madera para la proteccion subsiguiente.
CO4920220A1 (es) Composiciones que contienen compuestos fluoroeter y metodos para inhibir su degradacion en presencia de un acido de lewis
ES2098921T3 (es) Composiciones de cetoconazol de uso topico.
AR012172A2 (es) Composiciones farmaceuticas que comprenden analogos de lactacistina y uso de los mismos para la fabricacion de un medicamento
AR011116A1 (es) Compuesto derivado de n-hidroxi-beta-sulfonil propionamida y composicion farmaceutica que lo contiene
UY26092A1 (es) Uso de inhibidores de cyp2d6 en terapias de combinacion
ES2171428T3 (es) Derivados de galantamina, un procedimiento para su preparacion y su uso como medicamentos.
PT84823B (pt) Processo para a preparacao de novos derivados de imidazois 1-substituidos com accao inibidora da dopamina-beta-hidroxilase e de composicoes farmaceuticas que os contem
NO985679D0 (no) Dihydrobenzopyran og beslektede forbindelser nyttige som anti-inflammasjonsmidler
AR009809A1 (es) Derivados de 10,13,15-trioxatriciclo[9.2.1(9.6)]-pentadecanona, procedimientos para su preparacion y medicamentos que contienen estos compuestos
AR012546A1 (es) Utilizacion de al menos un compuesto seleccionado entre el grupo que comprende los sogaoles y los gingeroles para la preparacion de una composiciondesodorante, sogaol, extracto bruto y extracto purificado que contiene el sogaol y la composicion desodorante obtenida.
MX9302034A (es) Bencidazoles, medicamentos que contienen estos compuestos y procedimientos para su preparacion.
ES2116612T3 (es) Nuevas bis-naftalimidas para el tratamiento del cancer.
ES2177811T3 (es) Uso de nitroflavonoides para el tratamiento de la ansiedad.
ES2180751T3 (es) Inhibidor de metastasis de cancer.
ES2056789T3 (es) Inhibicion de la ruta de la 5-lipoxigenasa.
IL111966A0 (en) 4-Benzoylisoxazole derivatives, their preparation and herbicidal compositions containing them
ES2185708T3 (es) Inhibicion de la biosintesis de leucotrienos con derivados de urea.
AR022017A1 (es) Un agente para tratar el trastorno de la funcion de las celulas visuales. el metodo de tratamiento y el uso de dicho agente para la produccion de unacomposicion farmaceutica
IT8522359A0 (it) Composizioni farmaceutiche che li derivati di vitamina d,contengono e loro precursori.
AR008236A1 (es) Forma cristalina anhidra del clorhidrato de acido r(-)-n-(4,4-di(3- metiltien-2-il)but-3-enil)-nipecotico, una composicion farmaceutica y el uso de dicha sal cristalina para la preparacion de una composicion farmaceutica
UY26507A1 (es) Bases de mannich de 1-naftol y 2-naftol sustituidos, procedimiento para su preparación, medicamentos que contienen estos compuestos, así como el uso de estos compuestos para la preparación de medicamentos